Vivo Capital’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Vivo Capital’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-163,136	Closed	-$3.12M	–	54
2022 Q1	$3.12M	Sell	163,136 -163,136	-50%	-$2.91M	0.21%	45
2021 Q4	$8.26M	Sell	326,272 -83,728	-20%	-$2.45M	0.5%	39
2021 Q3	$13.4M	Buy	+410,000	New	+$14M	0.6%	30

Other funds holding DICE

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital's DICE Position: Q2 2022 in Review

Vivo Capital sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2022, closing a stake of 163,136 shares — an estimated $3.12M sold.

Vivo Capital first reported a position in DICE in Q3 2021 and held it in 3 quarters. The position peaked at $13.4M in Q3 2021. 80 funds tracked by Wall St. Rank hold DICE as of Q2 2022.

Vivo Capital reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Vivo Capital sold 163,136 DICE Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.12M.
Vivo Capital first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Vivo Capital's DICE Therapeutics, Inc. Common Stock position peaked at $13.4M in Q3 2021.
80 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Vivo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.